Card., I've said all along that the FDA should revise the Marine label. Amarin was induced to prove that beyond high trig, including Marine, that these patients had co-morbidity. It makes no sense for Vascepa to have one foot in the Marine door and the other in Reduce-it. By doing so, the FDA undermined Amarin, despite having Amarin jump through hoops...if the FDA wants to keep Marine for Lovaza only, let them, but Vascepa should not be in that class any longer.
The FDA is at the heart of this mess. It's far easier for them to close the loop hole than to have pharmas sueing each other endlessly.
ILT
News 
Market Data 
Discover 
AI
